The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.
Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.
“It offers a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services,” said Helen Knight, director of medicines evaluation at NICE.
Endometriosis affects around 1.5 million women in the UK. The condition occurs when tissue similar to the womb lining grows in other parts of the body. As this tissue breaks down during the menstrual cycle, it becomes trapped in the pelvis, causing chronic pain, fatigue, and a significant impact on quality of life.
According to NICE, Linzagolix works by blocking hormones that contribute to endometriosis symptoms.
Clinical trials have shown that, when taken with hormone therapy, the treatment can significantly reduce pelvic pain and painful periods.
Helen Knight noted that NICE’s streamlined evaluation process allowed for a faster review of the treatment, helping ensure that patients could access it quickly.
“Linzagolix is a valuable addition to the options available for this often painful and disruptive condition,” she said.
NICE compared Linzagolix’s costs with similar treatments and standard care options, concluding that it offers similar benefits at a comparable cost.
The medicine was approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on 14 March, 2025.
NICE will publish its final guidance on 25 June, after which the NHS in England will have 90 days to make the treatment available.
